See every side of every news story
Get Started
SubscribeLogin
Donald Trump
Everton
Volodymyr Zelenskyy
Ukraine War
Hamas
Viktor Orbán
Basketball
Israel-Hamas Conflict
Elon Musk
Javier Milei
Manchester United
Vladimir Putin
Published • loading... • Updated

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer - Bristol-Myers Squibb (NYSE:BMY)

Summary by Benzinga
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

2 Articles

All
Left
Center
1
Right
BenzingaBenzinga

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

·New York, United States
Read Full Article
Clinical Trials ArenaClinical Trials Arena

BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study

BMS has reported outcomes from the Phase III CheckMate -816 trial, indicating an OS benefit when Opdivo and chemotherapy is used.The post BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Wednesday, February 19, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
Search
BlindspotLocal